^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Thyroid Gland Carcinoma
    Drug:TAK‐632 (pan-RAF inhibitor, RIPK1 inhibitor, RIPK3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Cell
    Title:

    An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling

    Excerpt:
    Furthermore, in BRAFV600E colorectal and thyroid cancer cells lines in which VEM was ineffective, all treatments including TAK and LY led to potent suppression of cell growth within 10 days of treatment (Figure 7E).
    DOI:
    10.1016/j.ccell.2016.06.024